Kathy L. de Graaf, Geneviève Lapeyre, Florence Guilhot, Walter Ferlin, Stuart M. Curbishley, Marco Carbone, Paul Richardson, Sulleman Moreea, C. Anne McCune, Stephen D. Ryder, Roger W. Chapman, Annarosa Floreani, David E. Jones, Cristina de Min, David H. Adams, Pietro Invernizzi – 23 March 2018 – NI‐0801 is a fully human monoclonal antibody against chemokine (C‐X‐C motif) ligand 10 (CXCL10), which is involved in the recruitment of inflammatory T cells into the liver. The safety and efficacy of NI‐0801 was assessed in patients with primary biliary cholangitis.

Yichao Zhao, Fang Wang, Lingchen Gao, Longwei Xu, Renyang Tong, Nan Lin, Yuanyuan Su, Yang Yan, Yu Gao, Jie He, Lingcong Kong, Ancai Yuan, Ying Zhuge, Jun Pu – 23 March 2018 – Nonalcoholic fatty liver disease (NAFLD), characterized by hepatic steatosis (HS), insulin resistance (IR), and inflammation, poses a high risk of cardiometabolic disorders. Ubiquitin specific protease 4 (USP4), a deubiquitinating enzyme, is pivotally involved in regulating multiple inflammatory pathways; however, the role of USP4 in NAFLD is unknown.

Stephanie Barbara Schatz, Christoph Jüngst, Verena Keitel‐Anselmo, Ralf Kubitz, Christina Becker, Patrick Gerner, Eva‐Doreen Pfister, Imeke Goldschmidt, Norman Junge, Daniel Wenning, Stephan Gehring, Stefan Arens, Dirk Bretschneider, Dirk Grothues, Guido Engelmann, Frank Lammert, Ulrich Baumann – 22 March 2018 – Genetic variants in the adenosine triphosphate‐binding cassette subfamily B member 4 (ABCB4) gene, which encodes hepatocanalicular phosphatidylcholine floppase, can lead to different phenotypes, such as progressive familial intrahepatic cholestasis (PFIC) type 3, low phospholipid‐as

Stephanie Barbara Schatz, Christoph Jüngst, Verena Keitel‐Anselmo, Ralf Kubitz, Christina Becker, Patrick Gerner, Eva‐Doreen Pfister, Imeke Goldschmidt, Norman Junge, Daniel Wenning, Stephan Gehring, Stefan Arens, Dirk Bretschneider, Dirk Grothues, Guido Engelmann, Frank Lammert, Ulrich Baumann – 22 March 2018 – Genetic variants in the adenosine triphosphate‐binding cassette subfamily B member 4 (ABCB4) gene, which encodes hepatocanalicular phosphatidylcholine floppase, can lead to different phenotypes, such as progressive familial intrahepatic cholestasis (PFIC) type 3, low phospholipid‐as

Uttara Saran, Maria Guarino, Sarai Rodríguez, Cedric Simillion, Matteo Montani, Michelangelo Foti, Bostjan Humar, Marie V. St‐Pierre, Jean‐François Dufour – 22 March 2018 – Regular physical exercise has many beneficial effects, including antitumor properties, and is associated with a reduced risk of developing hepatocellular carcinoma (HCC). Less is known about the impact of exercise on HCC growth and progression.

Narjeet S. Khurmi, Yu‐Hui Chang, D. Eric Steidley, Andrew L. Singer, Winston R. Hewitt, Kunam S. Reddy, Adyr A. Moss, Amit K. Mathur – 15 March 2018 – Cardiovascular disease (CVD) is a leading cause of post–liver transplant death, and variable care patterns may affect outcomes. We aimed to describe epidemiology and outcomes of inpatient CVD care across US hospitals.

Myung Han Hyun, Young‐Sun Lee, Ji Hoon Kim, Chan Uk Lee, Young Kul Jung, Yeon Seok Seo, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun – 15 March 2018 – According to the American Association for the Study of Liver Diseases (AASLD) treatment guidelines for hepatocellular carcinoma (HCC), the role of surgery has been expanded beyond the Barcelona Clinic Liver Cancer (BCLC) algorithm. We compared primary hepatectomy (PH) with transarterial chemoembolization (TACE) in patients with intermediate‐ to advanced‐stage (BCLC stage B/C) HCC to determine the current evidence.

Elizabeth Carey – 15 March 2018

Lisa B. VanWagner, Fasiha Kanwal – 14 March 2018 – With the passage of the Affordable Care Act followed by the physician payment reform, there is an urgent need to better understand the complex relationships between structure (including incentives), processes, and outcomes of health care and, based on this understanding, identify interventions that can ensure delivery of high‐value care to patients with liver disease. As hepatologists, how do we systematically address these issues and ensure that we provide high‐value care to our patients?

Tiong Y. Lim, Enoka Gonsalkorala, Mary D. Cannon, Stella Gabeta, Leonie Penna, Nigel D. Heaton, Michael A. Heneghan – 14 March 2018 – Liver transplantation (LT) is a successful treatment for both acute liver failure and end‐stage liver disease. The number of women of reproductive age undergoing LT is increasing. Pregnancy outcomes are favorable, but there is still a lack of prognostic markers. We aimed to identify factors predictive of adverse pregnancy outcomes in LT recipients.